# Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL

> **NCT04883749** · PHASE2 · COMPLETED · sponsor: **German CLL Study Group** · enrollment: 53 (actual)

## Conditions studied

- Chronic Lymphoid Leukemia

## Interventions

- **BIOLOGICAL:** Acalabrutinib

## Key facts

- **NCT ID:** NCT04883749
- **Lead sponsor:** German CLL Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-01
- **Primary completion:** 2025-05-08
- **Final completion:** 2025-05-08
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04883749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04883749, "Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04883749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*